Relationship between serum levels of tumour necrosis factor-related apoptosis-inducing ligand and the survival of Chinese peritoneal dialysis patients
Article first published online: 24 JUN 2012
© 2012 The Authors. Nephrology © 2012 Asian Pacific Society of Nephrology
Volume 17, Issue 5, pages 466–471, July 2012
How to Cite
POON, P. Y.-K., SZETO, C.-C., KWAN, B. C.-H., CHOW, K.-M., LEUNG, C.-B. and LI, P. K.-T. (2012), Relationship between serum levels of tumour necrosis factor-related apoptosis-inducing ligand and the survival of Chinese peritoneal dialysis patients. Nephrology, 17: 466–471. doi: 10.1111/j.1440-1797.2012.01605.x
- Issue published online: 24 JUN 2012
- Article first published online: 24 JUN 2012
- Accepted manuscript online: 4 APR 2012 02:48AM EST
- Accepted for publication 18 March 2012.; Accepted manuscript online 4 April 2012.
- cardiovascular disease;
- renal failure
Aim: Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) can counteract inflammation and atherosclerosis, both common causes of morbidity in peritoneal dialysis (PD) patients. We examined the relation between serum soluble TRAIL (sTRAIL) levels and the outcome of Chinese PD patients.
Methods: We studied 116 new PD patients (67 males, age 56.7 ± 13.4 years). Baseline serum sTRAIL level was determined and grouped to tertiles 1 (lowest) to 3 (highest). All patients were followed for 20.9 ± 7.0 months.
Results: Patient survival was 83.4%, 74.2% and 100% for tertiles 1 to 3, respectively, at 24 months (P = 0.021). Multivariate Cox regression analysis showed that serum sTRAIL level was an independent predictor of patient survival after adjusting for confounding factors (adjusted hazard ratio 0.962, 95% confidence interval [CI] 0.935–0.991, P = 0.010).
Conclusion: A higher baseline serum sTRAIL level was associated with a better survival of PD patients. The detailed mechanism deserves further investigation.